Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health, Inc. (Nasdaq: HROW), a pharmaceutical company specializing in eyecare, announced participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations webpage starting at 7:00 a.m. ET on that date and archived for 90 days. Additionally, management will engage in one-on-one meetings during the conference, which interested investors can request through H.C. Wainwright.
Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $23.3 million for Q2 2022, a 29% increase from $18.1 million the previous year. The gross profit also hit a record at $16.8 million, a 22% rise from $13.7 million year-over-year. The company shipped 718,000 product units, which is a 4% year-over-year increase. However, Harrow reported a net loss of $6.2 million compared to $3 million last year. Cash and cash equivalents stood at $46.4 million as of June 30, 2022, as the company looks forward to key events in the second half of the year.
Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q2 ended June 30, 2022 on August 9, 2022, after market close. A Letter to Stockholders will be available on its website. Following this, a conference call will occur at 4:45 p.m. ET to discuss the results and provide a business update. Investors can participate through dial-in or via live webcast. The telephonic replay will be available until August 16, 2022, and the webcast replay until November 9, 2022.
Harrow Health, Inc. (NASDAQ: HROW) has successfully transferred the New Drug Applications (NDAs) for three FDA-approved ophthalmic medicines: IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Both IOPIDINE 1% and MAXITROL are now commercially available, with MOXEZA set for later release. This move follows their acquisition of these products in December 2021, during which Harrow began receiving net profits from sales. CEO Mark L. Baum expressed optimism about market interest and plans for commercial strategies targeting healthcare professionals and payers.
Harrow Health (NASDAQ: HROW) reported a record revenue of $22.1 million for Q1 2022, marking a 43% increase from $15.4 million in Q1 2021. The gross profit reached $16.2 million, up 38% year-over-year. A total of 689,000 product units were shipped, a 72% increase from the prior year. Despite a net loss of $2.4 million, the company anticipates a strong year driven by organic growth and plans for AMP-100's FDA review on October 16, 2022. Cash and equivalents stood at $42 million as of March 31, 2022.
Melt Pharmaceuticals announced favorable top-line results from its phase 1 PK study of MELT-210, a 3 mg sublingual midazolam tablet. The study involving 23 patients compared MELT-210 with IV midazolam and achieved concentration goals. CEO Larry Dillaha expressed optimism about the results, viewing it as a milestone for an IV-free sedation option. The next step includes discussions with the FDA regarding further clinical development. MELT-210 utilizes Catalent's proprietary Zydis® technology, with no FDA-approved equivalent products.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW) announced participation in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference. CEO Mark L. Baum and CFO Andrew Boll will present virtually on April 27, 2022, at 2:00 p.m. ET. A live webcast will be accessible on Harrow's website, with a replay available post-event. Harrow Health focuses on ophthalmic healthcare, owning ImprimisRx and Visionology, and holds equity in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q1 2022 on May 5, 2022, post market close. The company, which focuses on ophthalmic healthcare, will also host a conference call at 4:45 PM ET to discuss the results and provide a business update. A webcast will be available for replay until August 5, 2022. Details of the event, including participation dial-ins and replay options, can be found on their website. This update is pertinent for investors and stakeholders tracking financial performance and corporate developments.
Harrow Health, Inc. (HROW) has appointed Perry J. Sternberg and Dr. Marty Makary to its Board of Directors, effective immediately, while Robert J. Kammer has resigned. Sternberg brings extensive commercial experience from leading eye care companies, and his expertise in strategic marketing is expected to aid in launching new FDA-approved products like AMP-100. Dr. Makary, with a strong background in healthcare policy and innovation, aligns with the company's mission of making medicines accessible. This restructuring aims to strengthen governance and support Harrow's goal of becoming a leading U.S. eye care company.
Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $20.2 million for Q4 2021, marking a 38% increase year-over-year. Gross profit also reached $15.1 million, a 42% rise, with a gross margin of 75%. The FDA accepted the NDA for AMP-100 with a PDUFA target date of October 16, 2022. Commissions from DEXYCU® sales hit $1.0 million, driven by record unit volumes. The company ended 2021 with $42.2 million in cash and equivalents, providing a strong foundation for future growth.